The ability to affect gene expression via topical therapy has profound therapeutic implications for conditions characterized by open wounds including cutaneous neoplasms, thermal injury, skin disorders and dysfunctional wound healing. Specifically targeting local gene expression avoids systemic toxicity and simplifies treatment. We have developed a new method of topical matrix-based short interfering RNA application to precisely and effectively silence local gene expression in nondelimited wounds.
The discovery of RNA interference and short interfering RNA (siRNA) in Caenorhabditis elegans, 1 unveiled novel therapeutic possibilities. Unrestricted systemic [2] [3] [4] [5] and mucosal delivery [6] [7] [8] [9] as well as subretinal 10 applications have been successful, but targeted delivery to nondelimited regions such as cutaneous wounds remains unproven and untested. Topical delivery of siRNA can strategically modulate local gene expression in a variety of cutaneous disorders while avoiding systemic side effects. Since open wounds represent a substantial biomedical burden and offer a target-rich environment for candidate gene manipulation, we developed a matrix-based method to precisely and effectively deliver siRNA to cutaneous areas and tested it in a mouse model. Our novel method of topical siRNA delivery system avoids the limitations of electroporation or gene guns and the proviso of viral-mediated therapy. Successful delivery of siRNA in a nondelimited, topical fashion significantly expands the realm of in vivo gene therapy, potentially impacting cutaneous derangements ranging from non-healing wounds to neoplasms.
We developed an agarose matrix system to deliver a siRNA-liposomal transfection complex to nondelimited cutaneous wounds. The agarose matrix is an FDA approved 12 kDa natural colloid seaweed extract composed of agarobiose linear polysaccharide moieties with an extensive safety record in laboratory use. 11 Candidate siRNA was complexed with a liposomal transfection reagent and incorporated into a cooling (o371C) 0.4% (w/v) liquid agarose mixture. 12 The dose of siRNA and ratio of liposomal transfection reagent was established in preliminary studies. The optimal formulation was determined to be the least concentration of siRNA necessary for efficacy and most favorable carrier matrix handling properties. Concentrations of siRNA below that used resulted in partial inhibition of gene expression whereas higher concentrations provided no additional effect on the protein level. Cross-section of the doped agarose colloidal matrix demonstrates homogeneous distribution of fluorescein-labeled siRNA (Figure 1a) . In vitro, siRNA release from the agarose colloidal matrix approaches zero-order kinetics over the first 6 h, and then approximates first-order kinetics to at least 5 days (Figure 1b) . A previously described murine model of excisional wound healing was utilized because of its analogy to human wound healing. This model uses a silicon splint to counteract rapid wound contraction and allow for the development of granulation tissue with the resulting benefit of prolonged, but eventual healing. Histology of wound healing in this model closely parallels that in humans. 13 Granulation tissue, largely composed of fibroblasts, is easily targeted for gene silencing. The healed wound is normal, stable, epithelialized scar tissue, which has contracted the original wound by approximately 50%.
Paired 4 mm diameter wounds were created on the depilitated dorsum of a mouse, stented with a 12-mm Oring and covered with a transparent sterile occlusive dressing (Figure 1c ). Twenty-four hours later, 20 pmol of candidate siRNA doped into the cooling matrix was applied onto the wound bed and allowed to gel, with control wounds receiving gel alone (saline/no gel controls not shown). On post-injury day 5, the siRNAagarose matrix was removed and the wound re-covered with occlusive dressing alone. Forty-eight hours later, a second occlusive siRNA-agarose matrix was applied. Wounds (+2 mm border) were harvested on post-injury days 14 and 21. Tissue was analyzed for target mRNA and protein suppression. Mapk-1 and lamin A/C were chosen as target genes owing to their ubiquitous nature and high levels of expression. Moreover, the potentially confounding effects of phenotypic changes were avoided by the choice of these genes, which have no known impact on the wound healing phenotype. Immunohistochemistry demonstrated marked reduction of mapk-1 in the wound bed at 14 and 21 days ( Figure  2a ). Mapk-1 expression was not affected in the epithelial penumbra surrounding the treated wound (Figure 2b ). This observation demonstrates that the agarose matrix system precisely delivered siRNA to nondelimited areas.
Moreover, this specificity may account for the difference between target siRNA suppression observed in situ and the real time RT-PCR results on the wound with 2 mm of untreated perimeter tissue. Limiting siRNA delivery to the area subjacent to the agarose matrix system may allow targeting of critical genes that cannot be safely or easily silenced systemically. Because of the versatility of the agarose matrix system, similar candidate protein suppression can be achieved by doping the system with other alternate siRNAs. For example, lamin A/C siRNA effectively suppressed ubiquitously expressed lamin A/C (Figure 2c) .
Western blot analysis of whole wound homogenate (includes 2 mm of untreated perimeter tissue) at 14 and 21 days post-injury demonstrated marked reduction of mapk-1 and lamin A/C expression compared to shamtreated wounds (Figures 2d and e) . In situ hybridization (DEC) demonstrates a marked reduction in mapk-1 in the dorsal wound bed (section from wound center, wound periphery not visible) of treated animals compared to controls at 14 days. To construct the probes, DNA templates were prepared from total RNA of fibroblasts by reverse transcription-polymerase chain reaction (RT-PCR). PCR primers were designed to expand the desired MAPK sequence. The product was cloned into the pCRII-TOPO vector, and transformed into One Shot Chemically Competent E. coli (Invitrogen) according to the manufacturer's protocol. The transformed cells were grown, and the plasmid recovered at a concentration of 100 ng/ml using the Qiagen miniprep kit. The plasmids were linearized using BamH1 for the antisense probe and EcoRV for the sense probe. The riboprobes were synthesized at a concentration of 1 mg/ml by in vitro transcription of the linearized plasmid with digoxygenin-labeled nucleotides using T7 polymerase to make the sense probe, and SP6 polymerase to make the antisense probe. The MAPK sense probe was used as a negative control, MAPK antisense probe was used as the experimental probe and a b-actin antisense probe was used as the positive control. (e) mRNA was extracted from wound homogenate, including a 2 mm of untreated perimeter tissue as per the manufacturer's protocol (Ribopure Kit, Ambion, Austin, TX, USA) from treated and control mice. The quality and quantity of the RNA was assessed using a Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA), and typically 2 mg of total RNA was reverse-transcribed using Superscript II (Invitrogen) and oligo(dt) primers, according to the manufacturer's protocol. Real-time PCR was performed using 1 ng of reverse-transcribed cDNA per sample using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). SYBR green was used to detect PCR products (SYBR Green PCR Master Mix, Applied Biosystems). All reactions were performed in triplicate. The following primers were used: MAPK-1 forward 5 0 -CACCCATACCTGGAGCAGTA-3 0 , MAPK-1 reverse5 0 -GTCGTCCAACTCCATGTC AA-3 0 ; EIF4B forward 5 0 -CCTGAGCCAAAGAAACCTGA-3 0 , EIF4B reverse 5 0 -TCCACAGACAGAGCAGCGTA-3 0 . Mapk-1 expression was reduced 49-62% in treated wounds (n ¼ 3) vs sham wounds (n ¼ 3). a ¼ 0.05, P ¼ 0.003 (t-test). (f) mRNA was extracted from whole organ homogenate from treated and control mice and analyzed by real-time RT-PCR, as described previously. There was no statistically significant difference in mapk-1 expression between treated (n ¼ 3) and nontreated (n ¼ 3) controls. a ¼ 0.05, P ¼ 0.68 (liver), 0.63 (lung), 0.31 (spleen) (oneway analysis of variance). Error bars represent s.d. for all figures. MAPK, mitogen-activated protein kinase; PBS, phosphate-buffered saline; siRNA, short interfering RNA. Matrix-based siRNA silences local gene expression VD Thanik et al (20 pmol) candidate siRNA. This finding is important because low-dose siRNA minimizes interferon response. 14 Time to wound closure, the definitive measure of complete re-epithelialization in this model 13 was 28 days (+/À1 days) in both control and treated groups. A week after complete wound healing (35 days), there was no difference in treated groups compared to controls in either mapk or lamin A/C (immunohistochemistry and western blot).
These results demonstrate effective silencing of ubiquitously expressed genes in an open wound bed with a topically applied siRNA delivery system. Only the local targeted environment was affected. By design, the wound border served as a built-in lateral barrier to the system. The potential applications of wound bed gene silencing are enormous. For example, well-known apoptotic derangements 15 that occur in diabetic wounds can be targeted with this technique. Alternatively, genes unique to bacteria or viruses 16 can be targeted in a topical antibiotic preparation. Wounds prone to hypertrophic scaring and keloid formation can receive targeted gene therapy immediately after surgical excision. Ulceration, an indication for treatment of hemangiomas, provides a wound bed ideally suited to angiostatic therapies. Pyoderma granulosum is notoriously difficult to treat and provides a site for immunomodulation. Furthermore, many cutaneous neoplasms characteristically ulcerate, providing a unique opportunity for the introduction of targeted topical gene silencing strategies.
This versatile model is ideally suited for matrix substitution and siRNA modification. 4, 17 While these studies were performed with a single naked siRNA, chemical modifications or multiple siRNAs could be used to improve resistance to endogenous RNases 4,17 or increase efficiency and reduce off-target effects. While we have demonstrated no systemic gene suppression, further studies could be performed to completely exclude off-target gene effects not examined in this study. Additionally, changes in transfection reagents, dosing frequency and siRNA concentration could optimize efficacy, in this and other target sites.
Transepidermal, transdermal, peridermal and iontophoretic delivery models are the subject of ongoing study. Eventually, off-the-shelf monomeric or polymeric disease-specific siRNAs may provide precise, local silencing of conventionally non-druggable targets, thereby establishing gene silencing as the basis of future therapeutics in the treatment of wounds and cutaneous disorders. With carrier modification, matrix-based siR-NA could also be delivered intraluminally, intravascularly, and intraparenchymally.
